Goldspink
Geoffrey Goldspink, Hartfordshire GB
Patent application number | Description | Published |
---|---|---|
20130210723 | Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage - The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium. | 08-15-2013 |
Lachlan Goldspink, Sydney AU
Patent application number | Description | Published |
---|---|---|
20140130316 | Fasteners and Other Assemblies - The invention discloses several types of fastener, fastening systems, fastener assemblies and related areas. | 05-15-2014 |
Lachlan Richard Goldspink, Sydney AU
Patent application number | Description | Published |
---|---|---|
20140166018 | NASAL MASK SYSTEM - A forehead support for a respiratory mask includes a forehead support arm structured to extend from a frame and a forehead support pad provided to the arm. The forehead support pad includes upper headgear connectors adapted to engage upper headgear straps and a flexible region. The upper headgear connectors are constructed of a first material and the flexible region is constructed of a second material that is more flexible than the first material to allow adjustment of the distance of the forehead support pad from the patient's forehead in use. | 06-19-2014 |
20140174448 | NASAL MASK SYSTEM - A nasal cushion for a mask system includes a side wall defining a breathing chamber, an undercushion extending from the side wall, and a membrane that at least partially covers the undercushion. The membrane is adapted to seal along the nasal bridge, sides of nose, corners of nose, and upper lip of the patient's face in use. The undercushion is only provided along the side of nose, corner of nose, and upper lip regions of the cushion. The undercushion includes a flap or extending portion in each side of nose region that is wider than the other regions thereof and adapted to engage and provide a force into the sides of the patient's nose in use. | 06-26-2014 |
Lachlan Richard Goldspink, Wilmette AU
Patent application number | Description | Published |
---|---|---|
20110142570 | Stud Fastener and Stabilising Device - The invention relates to a stabilizing device ( | 06-16-2011 |
Lachlan Richard Goldspink, New South Wales AU
Patent application number | Description | Published |
---|---|---|
20080298887 | Panel and Clamping Fasteners - The invention provides a release for locking system particularly suitable for fastening a first element such as a panel ( | 12-04-2008 |
20090214316 | Stud Fastener and Stabilising Device - The invention relates to a stabilising device ( | 08-27-2009 |
20120080035 | ADJUSTABLE MASK SYSTEM AND RELATED METHODS - An adjustable mask system ( | 04-05-2012 |
Lachlan Richard Goldspink, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20100011548 | Fasteners and Other Assemblies - The invention discloses several types of fastener, fastening systems, fastener assemblies and related areas. | 01-21-2010 |
20110276472 | Closure for A Compartment - The invention provides a closures ( | 11-10-2011 |
20140040115 | Closure for A Compartment - The invention provides a closures ( | 02-06-2014 |
Lachlan Richard Goldspink, Bella Vista AU
Patent application number | Description | Published |
---|---|---|
20120138061 | NASAL MASK SYSTEM - A mask system includes a frame ( | 06-07-2012 |
Lincoln Mark Vaughan Goldspink, Newbury GB
Patent application number | Description | Published |
---|---|---|
20140026081 | CONTROLLING WEB PAGE BEHAVIOUR - A method of controlling webpage behaviour on a web enabled device | 01-23-2014 |
Lincoln Mark Vaughan Goldspink, Hampshire GB
Patent application number | Description | Published |
---|---|---|
20090024737 | WEBSITE MONITORING AND COOKIE SETTING - A method and apparatus for setting cookies on client devices | 01-22-2009 |
20090024748 | WEBSITE MONITORING AND COOKIE SETTING - A method and apparatus for setting cookies on client devices | 01-22-2009 |
Lincoln M. V. Goldspink, Hampshire GB
Patent application number | Description | Published |
---|---|---|
20090064173 | CONTENT MANAGEMENT - Method for receiving tailored pages, providing tailored pages and apparatus therefore. By way of illustrating the method for receiving tailored pages within a browser running on a client device, comprises the steps of: i) browsing, in the browser, pages from a page server; ii) sending from an active page in the browser to a monitoring server, at least one monitoring message including information concerning at least one of: interactions with and performance of at least one page browsed within the browser running on the respective client device; iii) receiving in the active page, from the monitoring server, a control message including an instruction to generate a cookie within the browser including selected monitoring information; iv) generating said cookie within the browser; v) sending a message to the page server, which message includes said cookie including the respective selected monitoring information; and vi) receiving from the page server, at least one page content item selected in dependence on the selected monitoring information included in the cookie. | 03-05-2009 |
Nicholas Goldspink, Manchester GB
Patent application number | Description | Published |
---|---|---|
20100137201 | MEDICAMENTS - There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided. | 06-03-2010 |
20100144690 | MEDICAMENTS AND METHODS FOR PROMOTING WOUND CONTRACTION - Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm | 06-10-2010 |
20100204248 | MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING - Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds. | 08-12-2010 |
20110166067 | METHODS FOR INHIBITION OF SCARRING - The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-β3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment TGF-β3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-β3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound. | 07-07-2011 |
Nick Goldspink, Manchester GB
Patent application number | Description | Published |
---|---|---|
20110082171 | Medicaments and Methods for Inhibition of Scarring - Provided is the use of an agonist of a GABA | 04-07-2011 |
Paul Goldspink, Northfield, IL US
Patent application number | Description | Published |
---|---|---|
20100158979 | TEMPORAL RELEASE OF GROWTH FACTORS FROM 3D MICRO ROD SCAFFOLDS FOR TISSUE REGENERATION - The present invention relates to the use of three-dimensional microrod scaffolds for the temporal release of growth factors useful in tissue regeneration, engineering and treatment of disorders. | 06-24-2010 |
20130210723 | Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage - The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium. | 08-15-2013 |
Robert John Goldspink, Kandos AU
Patent application number | Description | Published |
---|---|---|
20140234063 | DUCKBILL EJECTOR - A duckbill pod ( | 08-21-2014 |